Krystal Biotech Inc (KRYS) valuation
Krystal Biotech P/E ratio history
Krystal Biotech trades at 41.7 times its earnings over the last twelve months and 40.2 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 36.0 (year to Dec 2025) to 318.1 (year to Dec 2023), with a median of 52.2.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $246.54 | $6.84 | 36.0 | 33.8 |
| Dec 31, 2024 | $156.66 | $3.00 | 52.2 | 30.5 |
| Dec 31, 2023 | $124.06 | $0.39 | 318.1 | — |
| Dec 31, 2022 | $79.22 | -$5.49 | n/m | — |
| Dec 31, 2021 | $69.95 | -$3.13 | n/m | — |
| Dec 31, 2020 | $60.00 | -$1.70 | n/m | — |
| Dec 31, 2019 | $55.38 | -$1.22 | n/m | — |
| Dec 31, 2018 | $20.78 | -$0.97 | n/m | — |
| Dec 31, 2017 | $10.52 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Krystal Biotech valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Krystal BiotechKRYS | $9.80B | 41.7 | 40.2 | 22.2 |
| Madrigal PharmaceuticalsMDGL | $9.92B | — | — | 7.7 |
| Henry ScheinHSIC | $9.67B | 24.8 | 14.9 | 0.7 |
| Twist BioscienceTWST | $9.51B | — | — | 22.0 |
| Tg TherapeuticsTGTX | $9.37B | 22.3 | 33.5 | 11.7 |
| Protagonist TherapeuticsPTGX | $9.32B | 140.6 | 61.9 | 33.0 |
| InsuletPODD | $10.4B | 28.1 | 21.0 | 3.4 |
| Kymera TherapeuticsKYMR | $10.5B | — | — | 103.0 |
| Ensign GroupENSG | $10.6B | 27.0 | 21.3 | 1.9 |
| Peer median | 27.0 | 21.3 | 9.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: KRYS financials · KRYS returns
No forecast, no recommendation. This page describes Krystal Biotech Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.